# Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Study · id `cardio:ct-nct06376916` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06376916](<https://clinicaltrials.gov/study/NCT06376916>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06376916

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 153 participants.

## Technical summary

Registry record NCT06376916. Randomized; double masking; primary purpose treatment. Start 2024-10-07 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 153 participants (planned count; ClinicalTrials.gov record NCT06376916, source copy `cardio:ctgov-nct06376916-2026-09-28`, retrieved 2026-10-26)
- Started: 2024-10-07 (actual) (ClinicalTrials.gov record NCT06376916, source copy `cardio:ctgov-nct06376916-2026-09-28`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT06376916, source copy `cardio:ctgov-nct06376916-2026-09-28`, retrieved 2026-10-26)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT06376916, source copy `cardio:ctgov-nct06376916-2026-09-28`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06376916, source copy `cardio:ctgov-nct06376916-2026-09-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06376916-2026-09-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
- Acronym: ATRIUM
- Condition: Tachycardia Atrial
- Condition: Atrial Fibrillation
- Condition: Atrial Flutter With Rapid Ventricular Response
- Intervention (Drug): Magnesium Sulfate 2 G
- Intervention (Drug): Magnesium Sulfate 4 G
- Intervention (Drug): Saline
- Lead sponsor: Wake Forest University Health Sciences
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Wake Forest University Health Sciences (`cardio:wake-forest-health-sciences`)

## Provenance

Content hash: 019233c5548fde329928e3b06ea322d4ad119e33cb05f3d3bdb8ad83d057666f
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
